Autolus Therapeutics PLC
NASDAQ:AUTL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.33
7.29
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AUTL stock under the Base Case scenario is 5.91 USD. Compared to the current market price of 3.33 USD, Autolus Therapeutics PLC is Undervalued by 44%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Autolus Therapeutics PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AUTL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Autolus Therapeutics PLC
Balance Sheet Decomposition
Autolus Therapeutics PLC
Current Assets | 804.3m |
Cash & Short-Term Investments | 758.5m |
Receivables | 32m |
Other Current Assets | 13.8m |
Non-Current Assets | 97.1m |
PP&E | 92.5m |
Other Non-Current Assets | 4.6m |
Current Liabilities | 44m |
Accounts Payable | 1.4m |
Accrued Liabilities | 42m |
Other Current Liabilities | 570k |
Non-Current Liabilities | 275.4m |
Other Non-Current Liabilities | 275.4m |
Earnings Waterfall
Autolus Therapeutics PLC
Revenue
|
10.5m
USD
|
Operating Expenses
|
-185.5m
USD
|
Operating Income
|
-175m
USD
|
Other Expenses
|
-46.3m
USD
|
Net Income
|
-221.3m
USD
|
Free Cash Flow Analysis
Autolus Therapeutics PLC
USD | |
Free Cash Flow | USD |
Autolus Therapeutics is making significant strides with obe-cel, focusing on regulatory reviews in the U.S., Europe, and now the U.K., with a PDUFA date set for November 16th. The company is running two promising Phase 1 trials for pediatric ALL and advanced systemic lupus. Financially, Autolus ended Q2 2024 with $705.9 million in cash, up from $239.6 million last year, despite a rise in net operating expenses to $58.9 million from $44.4 million in Q2 2023. With strong cash reserves, Autolus is well-capitalized to launch obe-cel and advance its pipeline .
What is Earnings Call?
AUTL Profitability Score
Profitability Due Diligence
Autolus Therapeutics PLC's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Autolus Therapeutics PLC's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
AUTL Solvency Score
Solvency Due Diligence
Autolus Therapeutics PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Autolus Therapeutics PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AUTL Price Targets Summary
Autolus Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for AUTL is 10.61 USD with a low forecast of 7.07 USD and a high forecast of 13.65 USD.
Dividends
Current shareholder yield for AUTL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
Contact
IPO
Employees
Officers
The intrinsic value of one AUTL stock under the Base Case scenario is 5.91 USD.
Compared to the current market price of 3.33 USD, Autolus Therapeutics PLC is Undervalued by 44%.